Cuba applied more than10 million COVID-19 vaccine doses

Cuba sells another 4.5 million doses of Abdala vaccine to Mexico

HAVANA, Aug 4th Cuba exceeded 10 million doses of COVID-19 candidate vaccines developed in the country to face the pandemic, reported the Ministry of Public Health (Minsap).

Figures released by this entity indicate that at the end of the 1st day, a total of 10 million 61 thousand 236 doses of the Soberana 02 and Soberana Plus projects, developed by the Finlay Vaccine Institute (IFV) and the first Cuban vaccine, had been administered and from Latin America, Abdala, belonging to the Center for Genetic Engineering and Biotechnology (CIGB).

In this way, four million 155,261 people in the country have already received at least the first injection of any of these products during the mass vaccination processes, health intervention, intervention studies or clinical trials.

In addition, three million 225,507 Cubans have the second dose and another 2,680,468 with the third dose, the latter completing the complete immunization scheme, which represents 23.9 percent of the island’s inhabitants (plus of 11,300,000).

With the previous digits, the Caribbean nation exceeds the world average of vaccinated people.

According to the international site Our World in Data, more than seven months after starting immunization, only 28.6 percent of the population of the entire world has received at least one dose of the vaccine against COVID-19 and 14.8 percent are fully vaccinated.

In general, the immunization process ended in 20 Cuban municipalities: the special Isla de la Juventud, 15 in Havana and four in the eastern province of Santiago de Cuba.

With more than one million 355 thousand people who have the complete scheme, Havana concluded the vaccination process the day before, explained in a television press conference, Dr. María Elena Soto Entenza, head of the Department of Primary Health Care of the (Minsap).

Although the process is officially over, some vaccinations will remain open in the capital for those who have not been able to attend to receive their doses, he explained.

Abdala, applied at zero, 14 and 28 day intervals, showed 92.28 percent efficacy in phase III clinical trials against symptomatic disease.

This formulation, which has already received authorization from the regulatory authority of Cuba for emergency use, also showed 100 percent effectiveness in the face of severity and death.

For its part, the union of the candidate Soberana 02 with Soberana PLUS demonstrated 91.2 percent efficacy in phase III studies regarding the ability to prevent symptomatic disease and 100 percent against severity and death. It also showed 75.7 percent effectiveness against contagion. ( PL)